Inotiv, Inc. filings document the regulatory record of an operating contract research organization with Discovery and Safety Assessment and Research Models and Services operations. Current reports furnish financial results and business updates, including segment-related discussion for nonclinical and analytical drug development services, research models, and related products.
Material-event filings also describe credit-agreement administration, including waivers tied to minimum liquidity covenants, Nasdaq listing-compliance notices, shareholder voting matters, and governance disclosures. The filings provide formal records of capital-structure obligations, operating results, risk-related events, and public-company compliance matters for NOTV common stock.
Inotiv, Inc. amended its credit agreement to add a new $40.0 million bridge term loan facility and drew $27.5 million to repay about $14.3 million of existing revolving borrowings, terminate revolving commitments, and fund strategic alternatives, fees and working capital.
Lenders granted temporary covenant relief, waived certain cross-defaults tied to a missed interest payment on 3.25% Convertible Senior Notes due 2027, and extended the notes’ interest payment grace period to May 29, 2026. A Special Committee of independent directors was formed, with three members each receiving $40,000 per month to oversee recapitalization, restructuring, refinancing or other strategic options.
The Board approved an Executive Retention Plan and related key employee plan with potential payments up to $3,934,000, including a $1.2 million lump-sum bonus for CEO Robert Leasure Jr., subject to clawback under specified termination and potential Chapter 11 outcomes. Inotiv also agreed to a proposed, insurance-funded settlement of an Indiana state privacy class action related to its August 2025 cybersecurity incident, which remains subject to court approval.
Inotiv, Inc. reports weaker results and mounting financial pressure for the quarter and six months ended March 31, 2026. Total revenue for the six months was $238.5 million, slightly below $244.2 million a year ago, while the six‑month net loss widened to $60.8 million from $42.5 million. Heavy interest expense of $27.5 million and other operating costs drove an operating loss of $35.6 million.
Cash and cash equivalents fell to $15.2 million, and the company used $6.5 million of cash in operating activities over six months. Total debt of about $416.3 million has been classified as current because major facilities and Second Lien Notes mature within the next 12 months and covenant compliance is at risk.
Inotiv’s Credit Agreement now includes a $30 million minimum liquidity covenant, for which lenders have granted short‑term waivers, and the company did not make a required April 15, 2026 interest payment of approximately $2.1 million on its Convertible Senior Notes, which remains within its grace period. Management’s fiscal 2026 plan forecasts further covenant noncompliance, and they explicitly conclude that substantial doubt exists about the company’s ability to continue as a going concern without a liquidity‑enhancing transaction or debt restructuring.
Inotiv, Inc. reports that its lenders have granted a waiver of the minimum liquidity covenant under its existing Credit Agreement for the May 1, 2026 and May 8, 2026 liquidity test dates. The waiver applies only to that covenant for those specific test dates, and all other provisions of the Credit Agreement remain unchanged.
Inotiv, Inc. reports that its lenders have granted a waiver of the minimum liquidity covenant under its existing Credit Agreement. The waiver applies specifically to the liquidity test dates of April 17, 2026 and April 24, 2026. The company states that the waiver is limited to this covenant for those two test dates, and confirms that no other provisions of the Credit Agreement were amended.
Inotiv, Inc. reports that its lenders have granted a waiver of the minimum liquidity covenant under its existing Credit Agreement. The waiver applies only to the liquidity test dates of April 3, 2026 and April 10, 2026. The company states that no other provisions of the Credit Agreement were amended by this limited waiver.
Inotiv, Inc. reports that its lenders have granted a waiver of the minimum liquidity covenant in its Credit Agreement for the March 20, 2026 and March 27, 2026 liquidity test dates. The waiver applies only to that covenant for those two dates, and all other terms of the Credit Agreement remain unchanged.
Inotiv, Inc. reports that its lenders granted a waiver of the minimum liquidity covenant in its Credit Agreement for the March 6, 2026 and March 13, 2026 liquidity test dates. The waiver applies only to this specific covenant on those dates, and no other Credit Agreement terms were amended.
This temporary waiver means lenders agreed not to enforce the usual minimum liquidity requirement on those test dates, providing short-term flexibility while keeping the broader financing arrangement in place.
Inotiv, Inc.’s Chief Financial Officer Beth A. Taylor reported an automatic share sale related to tax withholding. On the transaction date, 2,888 shares of common stock were sold at an average price of $0.2929 per share to satisfy tax obligations upon vesting of restricted stock units.
The sale was executed by the company under a pre-arranged Rule 10b5-1 instruction entered into during the period from September 11, 2024 to October 9, 2024. After this transaction, Taylor’s directly held stake stands at 145,480 common shares.
Inotiv, Inc. Chief Strategy Officer John E. Sagartz reported an automatic sale of company stock to cover taxes on vested restricted stock units. On this transaction date, 2,119 shares of common stock were sold at an average price of $0.2908 per share under a pre-set Rule 10b5-1 instruction. Following this tax-withholding sale, Sagartz directly held 735,697 shares of Inotiv common stock.